Immunis Closes $25 Million Series A-1 Financing Round
January 11, 2025 10:00 AM Eastern Standard Time
IRVINE, Calif.–(BUSINESS WIRE)–Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 clinical trials. Follow-on investments from all major existing investors, notably, Remiges Ventures, Continuum Health Ventures and BOLD Capital Partners were joined by new investments from LifeSpan Vision Ventures and JLS Fund among others, including a leading global insurance company.
“We are grateful for the support of our Board and investors for our mission to maximize health and minimize disease through the development of novel, stem cell-derived therapies”Post this
Mitigating muscle loss and improving metabolic function as we age are unmet medical needs. Following a successful Phase 1/2a clinical trial demonstrating the safety, tolerability and suggestive efficacy of IMM01-STEM in people with age-related muscle atrophy, the FDA granted permission to proceed with a Phase 2 clinical trial testing the efficacy of IMM01-STEM in ameliorating muscle loss and reversing metabolic dysfunction in sarcopenic, overweight and obese elderly people.
“Our Phase 1/2a data in nine elderly patients showed our therapy to be safe with no serious adverse events. Additionally, patients experienced striking improvements in quality-of-life measures related to physical function and pain as well as a clinically relevant increase in gait speed,” says Mark Cabato, Chief Business Officer of Immunis. “By running randomized, controlled studies in elderly populations with degenerative disease and metabolic dysfunction, we hope to demonstrate IMM01-STEM’s broad applicability in multiple medical conditions.”
Preclinical studies of Immunis’ novel therapy in aged mouse models of muscle disuse atrophy and metabolism were published in two notable journals, GeroScience and Aging Cell. The multi-active therapy was shown to reverse muscle atrophy, improve muscle function, enhance metabolism and decrease body and liver fat. Immunis is currently the leading biotech with the most advanced stem cell-derived multi-active biologic in human clinical trials.
“We are grateful for the support of our Board and investors for our mission to maximize health and minimize disease through the development of novel, stem cell-derived therapies,” adds Cabato.
Immunis is a private biotechnology company developing a novel immunomodulatory multi-active product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in multi-active secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
Contacts
(c)2024 Business Wire, Inc., All rights reserved.
